ArticleCancer cytopathology2026
Preanalytical variables affect predictive immunohistochemical biomarker testing in non-small cell lung carcinoma cytology specimens.
Article in Cancer cytopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral therapeutic targets for non-small cell lung carcinoma (NSCLC) rely on protein expression by immunohistochemistry (IHC). Most biomarkers are validated on formalin-fixed, paraffin-embedded (FFPE) tissue; however, cytologic specimens, including cell blocks (CBs), that are subject to preanalytical variables are increasingly used. The objective of this study was to evaluate predictive IHC biomarkers in NSCLC CBs and compare them with surgical pathology (SP) specimens.
methodsThe authors retrospectively reviewed NSCLC cytology specimens that underwent predictive IHC testing for hepatocyte growth factor receptor (c-MET), human epidermal growth factor receptor 2 (HER2), and programmed death-ligand-1 (PD-L1) between January 2019 and June 2025. IHC was performed on CBs that were centrifuged with equal amounts of ethanol and formalin before FFPE processing. Equal numbers of NSCLC SP specimens with available biomarker testing were included for comparison. Predictive IHC scores that were considered therapy-eligible were c-MET IHC 3+, HER2 IHC 3+, and PD-L1-positive tumor proportion scores. Statistical analyses were performed using the Fisher exact test, with p < .05 considered significant.
resultsThe cohort included 414 cases (cytology specimens, N = 212; SP specimens, N = 212 [60% biopsy, 40% resection]). Cytology specimens demonstrated a significantly higher proportion of strong 3+ c-MET expression (40%) compared with SP specimens (10%; p < .0001). Similarly, high PD-L1 expression was more frequent in cytology specimens (32% vs. 20%; p = .0079). HER2 expression was similar between groups, with no significant difference in HER2 IHC 3+ rates (p = .34).
conclusionsPredictive IHC testing is performed on NSCLC cytology to identify patients for therapeutic targets. The current study highlights the need for optimizing preanalytical variables in cytology specimen processing, even when testing FFPE CBs, to ensure the reliability of predictive IHC results that guide therapeutic decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.